|State||Published - 2018|
Bibliographical noteFunding Information:
Dr Thrift receives funding from the National Health & Medical Research Council of Australia (GNT1042600). G. Howard receives funding from the National Institutes of Health (NIH). Dr Yenari receives funding from the Department of Veterans Affairs Merit Grant.
Dr Bernhardt served as an Advisor on the DART Neuroscience trial (Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors) that was discontinued, attended the 2017 investigator meeting in Sydney, Australia, and established and cochaired the Stroke Recovery and Rehabilitation Roundtable. Dr Olivot received speaker fees from Bristol Myers Squibb and Pfizer, and serves as a consultant for Servier, Medtronic, and Astra Zeneca. Dr Pierot serves as a consultant for Balt, Microvention, and Penumbra. Dr Goyal serves as a consultant for Microvention, Stryker, and Medtronic Neurovascular, and as coprincipal investigator for ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) and SWIFT PRIME (Solitaire With the Intention For Thrombectomy as Primary Endovascular Treatment) trials. Medtronic provided a grant to University of Calgary toward the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration. Stryker provided a research grant to the University toward the UNMASK EVT study (Decision Making Under Uncertainty in the Management of Acute Stroke With Endovascular Thrombectomy: Applying Principles From Neuroeconomics). G.A. Ford reports speaking fees from Medtronic. Dr Amin-Hanjani reports research support from Edge Therapeutics for the NEWTON trial (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage) and from the National Institutes of Health (no compensation). The other authors report no conflicts.
- Quality of life
- White matter
ASJC Scopus subject areas
- Clinical Neurology
- Cardiology and Cardiovascular Medicine
- Advanced and Specialized Nursing